186 related articles for article (PubMed ID: 37234285)
21. Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo.
Benesch MG; Tang X; Venkatraman G; Bekele RT; Brindley DN
J Biomed Res; 2016 Jul; 30(4):272-84. PubMed ID: 27533936
[TBL] [Abstract][Full Text] [Related]
22. IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.
Johnson Z; Tarantelli C; Civanelli E; Cascione L; Spriano F; Fraser A; Shah P; Nomanbhoy T; Napoli S; Rinaldi A; Niewola-Staszkowska K; Lahn M; Perrin D; Wenes M; Migliorini D; Bertoni F; van der Veen L; Di Conza G
Cancer Res Commun; 2023 Apr; 3(4):576-591. PubMed ID: 37066023
[TBL] [Abstract][Full Text] [Related]
23. Validation of an LC-MS/MS method for the quantification IOA-289 in human plasma and its application in a first-in-human clinical trial.
Mameli M; Franchi J; Calusi G; Deken MA; Johnson Z; van der Veen L; Lahn M; Vezzelli A; Cardin R; Greco A; Breda M
J Pharm Biomed Anal; 2022 Aug; 217():114829. PubMed ID: 35636006
[TBL] [Abstract][Full Text] [Related]
24. Autotaxin in Pathophysiology and Pulmonary Fibrosis.
Ninou I; Magkrioti C; Aidinis V
Front Med (Lausanne); 2018; 5():180. PubMed ID: 29951481
[TBL] [Abstract][Full Text] [Related]
25. The Expression Regulation and Biological Function of Autotaxin.
Zhang X; Li M; Yin N; Zhang J
Cells; 2021 Apr; 10(4):. PubMed ID: 33921676
[TBL] [Abstract][Full Text] [Related]
26. Autotaxin and chronic inflammatory diseases.
Magkrioti C; Galaris A; Kanellopoulou P; Stylianaki EA; Kaffe E; Aidinis V
J Autoimmun; 2019 Nov; 104():102327. PubMed ID: 31471142
[TBL] [Abstract][Full Text] [Related]
27. Toluene diisocyanate: Induction of the autotaxin-lysophosphatidic acid axis and its association with airways symptoms.
Broström JM; Ye ZW; Axmon A; Littorin M; Tinnerberg H; Lindh CH; Zheng H; Ghalali A; Stenius U; Jönsson BA; Högberg J
Toxicol Appl Pharmacol; 2015 Sep; 287(3):222-31. PubMed ID: 26072274
[TBL] [Abstract][Full Text] [Related]
28. Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis.
Bain G; Shannon KE; Huang F; Darlington J; Goulet L; Prodanovich P; Ma GL; Santini AM; Stein AJ; Lonergan D; King CD; Calderon I; Lai A; Hutchinson JH; Evans JF
J Pharmacol Exp Ther; 2017 Jan; 360(1):1-13. PubMed ID: 27754931
[TBL] [Abstract][Full Text] [Related]
29. Autocrine lysophosphatidic acid signaling activates β-catenin and promotes lung allograft fibrosis.
Cao P; Aoki Y; Badri L; Walker NM; Manning CM; Lagstein A; Fearon ER; Lama VN
J Clin Invest; 2017 Apr; 127(4):1517-1530. PubMed ID: 28240604
[TBL] [Abstract][Full Text] [Related]
30. Autotaxin in ascites promotes peritoneal dissemination in pancreatic cancer.
Jinno N; Yoshida M; Hayashi K; Naitoh I; Hori Y; Natsume M; Kato A; Kachi K; Asano G; Atsuta N; Sahashi H; Kataoka H
Cancer Sci; 2021 Feb; 112(2):668-678. PubMed ID: 33053268
[TBL] [Abstract][Full Text] [Related]
31. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme.
Tabuchi S
Lipids Health Dis; 2015 Jun; 14():56. PubMed ID: 26084470
[TBL] [Abstract][Full Text] [Related]
32. Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.
Stein AJ; Bain G; Prodanovich P; Santini AM; Darlington J; Stelzer NM; Sidhu RS; Schaub J; Goulet L; Lonergan D; Calderon I; Evans JF; Hutchinson JH
Mol Pharmacol; 2015 Dec; 88(6):982-92. PubMed ID: 26371182
[TBL] [Abstract][Full Text] [Related]
33. Autotaxin-Lysophosphatidic Acid Axis Blockade Improves Inflammation by Regulating Th17 Cell Differentiation in DSS-Induced Chronic Colitis Mice.
Dong YL; Duan XY; Liu YJ; Fan H; Xu M; Chen QY; Nan Z; Wu H; Deng SJ
Inflammation; 2019 Oct; 42(5):1530-1541. PubMed ID: 31102124
[TBL] [Abstract][Full Text] [Related]
34. Autotaxin inhibition reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction.
Tripathi H; Al-Darraji A; Abo-Aly M; Peng H; Shokri E; Chelvarajan L; R Donahue R; Levitan BM; Gao E; Hernandez G; Morris AJ; Smyth SS; Abdel-Latif A
J Mol Cell Cardiol; 2020 Dec; 149():95-114. PubMed ID: 33017574
[TBL] [Abstract][Full Text] [Related]
35. Design and Development of Autotaxin Inhibitors.
Jia Y; Li Y; Xu XD; Tian Y; Shang H
Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832985
[TBL] [Abstract][Full Text] [Related]
36. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid.
Tanaka M; Okudaira S; Kishi Y; Ohkawa R; Iseki S; Ota M; Noji S; Yatomi Y; Aoki J; Arai H
J Biol Chem; 2006 Sep; 281(35):25822-30. PubMed ID: 16829511
[TBL] [Abstract][Full Text] [Related]
37. Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.
Nikolaou A; Ninou I; Kokotou MG; Kaffe E; Afantitis A; Aidinis V; Kokotos G
J Med Chem; 2018 Apr; 61(8):3697-3711. PubMed ID: 29620892
[TBL] [Abstract][Full Text] [Related]
38. Autotaxin signaling facilitates β cell dedifferentiation and dysfunction induced by Sirtuin 3 deficiency.
Cao H; Chung ACK; Ming X; Mao D; Lee HM; Cao X; Rutter GA; Chan JCN; Tian XY; Kong APS
Mol Metab; 2022 Jun; 60():101493. PubMed ID: 35398277
[TBL] [Abstract][Full Text] [Related]
39. Autotaxin-LPA receptor axis in the pathogenesis of lung diseases.
Chu X; Wei X; Lu S; He P
Int J Clin Exp Med; 2015; 8(10):17117-22. PubMed ID: 26770305
[TBL] [Abstract][Full Text] [Related]
40. Structural and PK-guided identification of indole-based non-acidic autotaxin (ATX) inhibitors exhibiting high in vivo anti-fibrosis efficacy in rodent model.
Lei H; Cao Z; Wu H; Li T; Wang X; Chen Y; Ma E; Sun L; Zhai X
Eur J Med Chem; 2022 Jan; 227():113951. PubMed ID: 34742015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
